DMD Warrior

Stay informed on #DMD cures, clinical trials, and #Duchenne muscular dystrophy research. Visit for updates and support.

[DMD Warrior @dmdwarriorcom]

Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing #saRNA Therapeutic for #Duchenne Muscular Dystrophy

Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of RAG-18 at Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences in Beijing. #DMD

👉📷 Read More: https://t.co/8VqdPieePn

[DMD Warrior @dmdwarriorcom]

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy

Atossa Therapeutics announced that the U.S. Food and Drug Administration (“FDA”) has granted Rare Pediatric Disease (“RPD”) designation to (Z)-Endoxifen for the treatment of Duchenne Muscular Dystrophy (“DMD”).

👉 Read More: https://t.co/8VqdPieePn

[DMD Warrior @dmdwarriorcom]

Satellos reported that the FDA and other global regulators have cleared its IND for SAT-3247, enabling a three-month Phase 2, placebo-controlled trial in 51 ambulatory children with Duchenne muscular dystrophy. #satellos #dmd #duchenne

👉 Read More: https://t.co/FwUBRAFUYO

[DMD Warrior @dmdwarriorcom]

Researchers Buel D. Rodgers and Christopher W. Ward published a groundbreaking study in Gene Therapy that unveiled a codon-optimized human Smad7 gene therapy aimed at treating Duchenne muscular dystrophy (DMD).

👉 Read More: https://t.co/FwUBRAFUYO

[DMD Warrior @dmdwarriorcom]

ELEVIDYS Gene Therapy for Non-Ambulant Children with DMD: FDA OKs ENDEAVOR Cohort 8 Immunosuppression Study

👉 Read More: https://t.co/FwUBRAGsOm

[DMD Warrior @dmdwarriorcom]

Potential of SAT-3247 to Restore Muscle Regeneration in Duchenne Published in Nature

👉Read More: https://t.co/FwUBRAFUYO

[DMD Warrior @dmdwarriorcom]

Ali Taghizadeh Announces DMD ANKA mRNA Therapy, Currently in Clinical Trial in Turkiye

DMD ANKA mRNA therapy, currently under development for Duchenne muscular dystrophy in Turkiye, was announced by Associate Professor Dr. Ali Taghizadeh.

👉Read More: https://t.co/FwUBRAFUYO

[DMD Warrior @dmdwarriorcom]

REGENXBIO Announces Completion of RGX-202 Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

#dmd #duchenne #regenxbio #genetherapy #clinicaltrials #rgx202

👉 Read More: https://t.co/FwUBRAGsOm

[DMD Warrior @dmdwarriorcom]

Hansa’ Imlifidase Reduce Anti-AAV Antibodies and Allow Administration of Gene Therapy

#dmd #duchenne #imlifidase #genetherapy #clinicaltrials

👉 Read More: https://t.co/FwUBRAGsOm

[DMD Warrior @dmdwarriorcom]

Why Elevidys Was Not Approved by the European Medicines Agency (EMA)?

You can access the comprehensive report on the reasons for the Elevidys refusal published by EMA from our web page link.

#dmd #duchenne #elevidys #eu

👉 Read More: https://t.co/FwUBRAFUYO

[DMD Warrior @dmdwarriorcom]

Brogidirsen (NS-089/NCNP-02) has The Potential to Slow Disease Progression in DMD Patients Amenable to Exon 44 Skipping

#dmd #duchenne #exon44 #brogidirsen

👉 Read More: https://t.co/FwUBRAFUYO

[DMD Warrior @dmdwarriorcom]

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

#dmd #duchenne #delzota #exon44 #exon44skipping #clinicaltrials #aviditybiosciences

👉 Read More: https://t.co/FwUBRAFUYO

[DMD Warrior @dmdwarriorcom]

Does Pulsed Electromagnetic Field (PEMF) Therapy Treat Duchenne Muscular Dystrophy and Initiate Dystrophin Production?

#pemf #dmd #duchenne

👉 Read More: https://t.co/FwUBRAFUYO

[DMD Warrior @dmdwarriorcom]

Tevard Biosciences Presents Data Demonstrating Production of Full-Length Protein with tRNA-Based Therapy for Duchenne Muscular Dystrophy

#dmd #duchenne

https://t.co/P9sJeJvaVP

[DMD Warrior @dmdwarriorcom]

Cures of #Duchenne (Detailed List of All Clinical Trials for #DMD)

List of all researches such as #gene therapy, exon skipping, reducing inflammation and improving #muscle growth & protection cures for duchenne #muscular dystrophy.

https://t.co/aroa4OzQQO

[DMD Warrior @dmdwarriorcom]

Del-zota (Exon 44 Skipping Therapy) Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in Phase 1/2 Trial

#dmd #duchenne #delzota #exon44 #exon44skipping #clinicaltrials #aviditybiosciences

👉 Read More: https://t.co/FwUBRAGsOm

[DMD Warrior @dmdwarriorcom]

Belief BioMed Announced Successful Completion of First Dose of BBM-D101 Gene Therapy

#dmd #duchenne #BBMD101 #BeliefBioMed #clinicaltrials

📷 Read More: https://t.co/FwUBRAGsOm

[DMD Warrior @dmdwarriorcom]

Solid Biosciences Initiates Phase 3 Clinical Trial of SGT-003 Gene Therapy (IMPACT DUCHENNE) in Ambulant Males

#dmd #duchenne #sgt003 #genetherapy #clinicaltrials

👉 Read More: https://t.co/FwUBRAGsOm

[DMD Warrior @dmdwarriorcom]

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

#dmd #duchenne #ker065

👉 Read More: https://t.co/FwUBRAGsOm

[DMD Warrior @dmdwarriorcom]

GNR-097: Duchenne Gene Therapy Phase 1/2 Study Started by Generium

#dmd #duchenne #gnr097 #genetherapy #clinicaltrials

👉 Read More: https://t.co/FwUBRAGsOm